-+ 0.00%
-+ 0.00%
-+ 0.00%

Traws Pharma posts FY25 net income of $9.2 million; revenue rises to $2.8 million

PUBT·04/15/2026 20:01:59
Listen to the news
Traws Pharma posts FY25 net income of $9.2 million; revenue rises to $2.8 million
  • Traws Pharma swung to net income of USD 9.2 million, versus a net loss of USD 166.5 million a year earlier.
  • Revenue climbed to USD 2.8 million; the increase was due to recognition of deferred revenue following termination of the Symbio license agreement.
  • Operating loss narrowed to USD 17.9 million from USD 142.4 million.
  • PIPE financing for up to USD 60 million closed April 15, including USD 10 million upfront, with additional proceeds tied to milestone-based and three-year warrants.
  • Cash and cash equivalents totaled USD 3.8 million at Dec. 31, 2025; financing and existing cash expected to fund operations into Q1 2027, including planned Phase 2a single-dose influenza human challenge trial for tivoxavir marboxil in Q2 2026 pending MHRA approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604151601PRIMZONEFULLFEED9690622) on April 15, 2026, and is solely responsible for the information contained therein.